Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04605731 | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | active not recruiting | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02954094 | A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | active not recruiting | — | 10,000 | Target PharmaSolutions, Inc.INDUSTRY | 5 | Apr 17, 2026 |
| clinicaltrials |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe) | active not recruiting | Phase 2 | 145 | Laura Huppert, MD, BAOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05081492 | CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 | 9 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT02863107 | Young-Onset Colorectal Cancer | active not recruiting | — | 818 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04940286 | Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | active not recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT00918775 | Follow-up After Metastasectomy in Patients With Kidney Cancer | active not recruiting | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02659241 | Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Early Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02876107 | Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03546972 | Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants | active not recruiting | N/A | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03821792 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04220827 | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer | active not recruiting | Phase 1 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04837118 | Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study | active not recruiting | N/A | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05055843 | Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer | active not recruiting | N/A | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05347212 | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT00119912 | NORCCAP: Norwegian Colorectal Cancer Prevention Trial(NORCCAP) | active not recruiting | N/A | 100,000 | Norwegian Institute of Public HealthOTHER_GOV | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05960578 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | active not recruiting | Phase 2 | 8 | University of WashingtonOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02688712 | ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer | active not recruiting | Phase 2 | 50 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | active not recruiting | Phase 2 | 50 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT04061980 | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | active not recruiting | Phase 2 | 24 | Providence Health & ServicesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04948437 | Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer | active not recruiting | — | 103 | National Taiwan University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05463107 | Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer | active not recruiting | — | 50 | National Taiwan University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05666271 | Radiofrequency Ablation for Hepatocellular Carcinoma Using Octopus MP Electrodes | active not recruiting | — | 76 | Seoul National University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT04180072 | Atezolizumab Plus Bevacizumab With HCC and HBV Infection | active not recruiting | N/A | 51 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05034887 | Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 64 | National Cancer Center Hospital EastOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | active not recruiting | Phase 2 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 8, 2026 | clinicaltrials |
| NCT04449406 | Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers(UroPanc) | active not recruiting | — | 3,500 | Queen Mary University of LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04496739 | Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE) | active not recruiting | N/A | 412 | SWOG Cancer Research NetworkNETWORK | 2 | Apr 7, 2026 | clinicaltrials |
| NCT05808608 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 37 | Hao ZengOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02673333 | Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma | active not recruiting | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05382299 | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer(ASCENT-03) | active not recruiting | Phase 3 | 623 | Gilead SciencesINDUSTRY | 30 | Apr 6, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | active not recruiting | Phase 2 | 350 | Actuate Therapeutics Inc.INDUSTRY | 7 | Apr 3, 2026 | clinicaltrials |
| NCT04916808 | The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing(AUS-PREDICT) | active not recruiting | — | 1,500 | PreludeDxINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05335993 | A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | active not recruiting | Phase 2 | 10 | CanariaBio Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06504615 | Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France(METAGIO) | active not recruiting | — | 208 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02664883 | Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer | active not recruiting | — | 37 | University of Southern CaliforniaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer(ADEPT) | active not recruiting | Phase 2 | 393 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05568472 | Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study | active not recruiting | N/A | 565 | SWOG Cancer Research NetworkNETWORK | 2 | Apr 2, 2026 | clinicaltrials |
| NCT04300855 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | active not recruiting | Phase 2 | 115 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04498117 | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery(FLORA-5) | active not recruiting | Phase 3 | 615 | CanariaBio Inc.INDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT05108428 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | active not recruiting | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05605535 | Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 88 | CanariaBio Inc.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT01525966 | Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer | active not recruiting | Phase 2 | 67 | City of Hope Medical CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT05622136 | Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma(STRAT-aHCC) | active not recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 20, 2026source: clinicaltrials